ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

Kennedy stoppar 22 projekt inom mRNA-vaccin – experter varnar för följderna

USA:s hälsodepartement avbryter finansieringen av 22 projekt som utvecklar mRNA-baserade vacciner, och växlar över till vad som hävdas vara ”säkrare och bredare...

USA:s regering skrotar vaccinavtal med Moderna

Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...

Swedish life science is growing – but capital is not keeping up

The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted co...

Vaccinprojekt mot medfödd infektion skrotas i sen fas – ”Klart besvikna”

Hoppet om det första vaccinet mot världens vanligaste medfödda infektion har fått sig en rejäl törn.

Pharma Outsourcing – Find the Right Partner (2025)

The Future of Metrology is Coming to Your Region

Join our event series.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

Gene therapy restored hearing in children with congenital deafness

Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Svenska biotechbolag i samarbete om biologiska läkemedel

AAX Biotech och Toxotech har ingått ett strategiskt samarbete för att utveckla nya biologiska läkemedel.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...